Ahead of releasing its first-quarter results on Thursday, Gilead disclosed yet another senior executive departure: longtime CFO Robin Washington, who unveiled plans to exit come March 2020. In parallel with the drugmaker’s announcement on Tuesday, Google’s parent company Alphabet unveiled Washington was set to serve on its board.

Robin Washington

The spate of departures at Gilead — which is looking to reinvigorate its growth engine as its once-titanic hep C franchise wanes — are beginning to resemble a mass exodus. Days after new chief Daniel O’Day started his run at the company’s helm last month, executive vice president of oncology Alessandro Riva revealed he was off to run a US-based biotech spinoff from India’s Glenmark. His exit was preceded by CEO John Milligan, chairman John Martin and R&D chief Norbert Bischofberger. Bischofberger’s replacement, Andrew Cheng, stepped up as chief medical officer at Gilead, only to leave to run his own biotech.

Washington will continue to serve as Gilead’s CFO and executive vice president while the company finds a replacement, and should a CFO be named before March 1, she will remain in an advisory capacity through the completion of the company’s reporting of 2019 financial results, the company $GILD said.

Washington’s move to Alphabet’s $GOOG board is pertinent. Prior to joining Gilead in 2008, she served as CFO of an enterprise software company called Hyperion Solutions, and before that held executive positions at PeopleSoft, an enterprise application software provider. Since 2013, she has also served as a director at technology and manufacturing firm Honeywell and customer relationship management technology maker Salesforce.com.

Sign in to Endpoints News

Request a magic link

Enter your email below to get a Magic link which lets you sign in quickly without using a password.Please note the Magic link is one-time use only and valid for only 24 hours.
Email:

← Go back

Set a new password

We will send you a link, with which you will be able to set a new password.Please note this link is for one-time use only and valid for only 24 hours.
Email:

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 51,200+ biopharma executives who read Endpoints News every day.